Artificial Intelligence to Facilitate Clinical Trial Recruitment in Age-Related Macular Degeneration
Ophthalmology Science · 2024-11 · 4 (6) · 100566
DOI: 10.1016/j.xops.2024.100566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology Science, 2024-11. Verfasst von Dominic J Williamson und 12 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, UK Research and Innovation, Innovate UK.
Abstract (Originalsprache)
Objective
Recent developments in artificial intelligence (AI) have positioned it to transform several stages of the clinical trial process. In this study, we explore the role of AI in clinical trial recruitment of individuals with geographic atrophy (GA), an advanced stage of age-related macular degeneration, amidst numerous ongoing clinical trials for this condition.
Design
Cross-sectional study. Subjects: Retrospective dataset from the INSIGHT Health Data Research Hub at Moorfields Eye Hospital in London, United Kingdom, including 306 651 patients (602 826 eyes) with suspected retinal disease who underwent OCT imaging between January 1, 2008 and April 10, 2023.
Methods
A deep learning model was trained on OCT scans to identify patients potentially eligible for GA trials, using AI-generated segmentations of retinal tissue. This method's efficacy was compared against a traditional keyword-based electronic health record (EHR) search. A clinical validation with fundus autofluorescence (FAF) images was performed to calculate the positive predictive value of this approach, by comparing AI predictions with expert assessments. Main Outcome Measures: The primary outcomes included the positive predictive value of AI in identifying trial-eligible patients, and the secondary outcome was the intraclass correlation between GA areas segmented on FAF by experts and AI-segmented OCT scans.
Results
The AI system shortlisted a larger number of eligible patients with greater precision (1139, positive predictive value: 63%; 95% confidence interval [CI]: 54%-71%) compared with the EHR search (693, positive predictive value: 40%; 95% CI: 39%-42%). A combined AI-EHR approach identified 604 eligible patients with a positive predictive value of 86% (95% CI: 79%-92%). Intraclass correlation of GA area segmented on FAF versus AI-segmented area on OCT was 0.77 (95% CI: 0.68-0.84) for cases meeting trial criteria. The AI also adjusts to the distinct imaging criteria from several clinical trials, generating tailored shortlists ranging from 438 to 1817 patients.
Conclusions
This study demonstrates the potential for AI in facilitating automated prescreening for clinical trials in GA, enabling site feasibility assessments, data-driven protocol design, and cost reduction. Once treatments are available, similar AI systems could also be used to identify individuals who may benefit from treatment. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
- Centre for Medical Image Computing, University College London, London, UK.
- Institute of Ophthalmology, University College London, London, UK.
- Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
- Department of Surgery (Ophthalmology), The University of Melbourne, Melbourne, Australia.
- Surrey Clinical Trials Unit, University of Surrey, Guildford, UK.
Förderung
- Medical Research Council
- UK Research and Innovation
- Innovate UK
Zitieren
APA
Williamson, D. J., Struyven, R. R., Antaki, F., Chia, M. A., Wagner, S. K., Jhingan, M., Wu, Z., Guymer, R., Skene, S. S., Tammuz, N., Thomson, B., Chopra, R., & Keane, P. A. (2024). Artificial Intelligence to Facilitate Clinical Trial Recruitment in Age-Related Macular Degeneration. Ophthalmology Science, 4(6), 100566. https://doi.org/10.1016/j.xops.2024.100566
Vancouver
Williamson DJ, Struyven RR, Antaki F, Chia MA, Wagner SK, Jhingan M, et al. Artificial Intelligence to Facilitate Clinical Trial Recruitment in Age-Related Macular Degeneration. Ophthalmology Science. 2024;4(6):100566. doi:10.1016/j.xops.2024.100566
BibTeX
@article{Williamson2024,
author = {Williamson, Dominic J and Struyven, Robbert R and Antaki, Fares and Chia, Mark A and Wagner, Siegfried K and Jhingan, Mahima and Wu, Zhichao and Guymer, Robyn and Skene, Simon S and Tammuz, Naaman and Thomson, Blaise and Chopra, Reena and Keane, Pearse A},
title = {Artificial Intelligence to Facilitate Clinical Trial Recruitment in Age-Related Macular Degeneration},
journal = {Ophthalmology Science},
year = {2024},
volume = {4},
number = {6},
pages = {100566},
doi = {10.1016/j.xops.2024.100566}
}
EUVIMED